The backtest results for ABVX following earnings beats show poor short-term performance with 0% win rates at 3 and 10 days and negative returns of -12.07% and -21.09%, respectively. However, the 30-day win rate improves to 50% with a slight negative return of -1.23%, indicating some recovery over a longer horizon. This suggests that immediate market reactions to ABVX earnings beats have been unfavorable, but longer-term outcomes are more balanced. Investors should be cautious about short-term trades post-earnings beat and consider a longer holding period for potential recovery.

backtest_data

The backtest results show that ABVX has a consistent 50% win rate across 3-day, 10-day, and 30-day periods following earnings misses, with returns of 12.11%, 1.61%, and 22.72% respectively. This indicates a mixed but potentially positive price reaction over the medium term despite the earnings miss. The maximum return of 74.04% occurring on day 33 suggests occasional strong rebounds. Investors might consider that ABVX can still offer significant upside opportunities after earnings disappointments, but with balanced short-term uncertainty.

The backtest results show that the Biotechnology Industry experienced a slight negative impact following earnings beats, with a maximum return of only 0.50% observed 15 days after the event. This suggests that despite positive earnings surprises, the sector's price reaction was muted and generally unfavorable over the tested period.

The analysis indicates that earnings beats in this industry do not translate into strong positive price momentum, possibly due to other overriding market factors or sector-specific risks.

Investors should be cautious about expecting significant gains solely based on earnings beats in the Biotechnology Industry.

The backtest results show that earnings misses in the Biotechnology Industry had no significant impact, with a maximum return of only 0.36% occurring three days after the event. This negligible effect suggests that the industry’s stock prices are largely unaffected by earnings misses over the tested period.

The analysis indicates that investors should not expect meaningful price movements in the Biotechnology sector following earnings misses, reflecting market resilience or other overriding factors.

For investors, this implies that earnings misses in this industry may not warrant reactive trading strategies or portfolio adjustments.

Backtest ABVX Earnings Beats and Misses Expectations

Find all upcoming company earnings reports scheduled for jun 01 2026. Get details on which companies are reporting and their expected results.

Calendar